

Supplementary Information

Reductive Cross-Coupling of *N*-Acyl Pyrazole and Nitroarene using tetrahydroxydiboron: Synthesis of Secondary Amides

Ha Yeon Moon, Sunwoo Lee*

† Department of Chemistry, Chonnam National University, Gwangju, 61186, Republic of Korea

Table of Contents

1. General information	S-2
2. General procedure for the synthesis of products	S-2
3. Characterization Data for the Products	S-3
4. References	S-20
5. ¹ H and ¹³ C NMR spectra of products	S-21


1. General Information

All reagents were purchased and used without further purification. ^1H NMR spectra were recorded in CDCl_3 or $(\text{CD}_3)_2\text{SO}$ on 500 MHz NMR spectrometers and data are reported as follows: chemical shift, multiplicity [singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), heptet (hept), doublet of doublets (dd), triplet of triplet (tt) and multiplet (m)], coupling constants (Hz) and integration. ^{13}C NMR spectra were recorded in CDCl_3 or $(\text{CD}_3)_2\text{SO}$ on 126 MHz NMR spectrometers and resonances (δ) are given in ppm. Starting materials of amides were synthesized according to corresponding literature.¹

2. General procedure for the synthesis of products

N-Acyl pyrazole (1 mmol, 1.0 equiv), nitroarene (1.0 mmol, 1.0 equiv), $\text{B}_2(\text{OH})_4$ (269 mg, 3.0 mmol, 3.0 equiv) were dissolved in DMF (5 mL, 0.2M). The resulting solution was stirred at 100 °C for 24 h. The reaction was diluted with ethyl acetate, then washed with brine. The organic layer was dried over MgSO_4 , filtered, and concentrated under vacuum. The crude product was purified by silica gel column chromatography with ethyl acetate/hexane (1:9).

3. Characterization Data for the Products



***N*-Phenylbenzamide (3aa)²**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3aa** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (171 mg, 0.87 mmol, 87%).

m.p. 162-163 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.27 (s, 1H), 7.99 – 7.97 (m, 2H), 7.82 – 7.80 (m, 2H), 7.61 – 7.57 (m, 1H), 7.55 – 7.52 (m, 2H), 7.38 – 7.34 (m, 2H), 7.10 (tt, *J* = 7.4, 1.25 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.58, 139.20, 135.02, 131.52, 128.59, 128.36, 127.66, 123.65, 120.38;

MS (EI) *m/z* = 197.08 (M⁺).



2-Methyl-*N*-phenylbenzamide (3ba)^[2]


According to the general procedure using (1H-pyrazol-1-yl)(*o*-tolyl)methanone (186 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ba** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (160 mg, 0.76 mmol, 76%).

m.p. 126-127 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 7.95 (s, 1H), 7.68 (s, 1H), 7.66 – 7.62 (m, 3H), 7.38 – 7.33 (m, 4H), 7.16 – 7.13 (m, 1H), 2.41 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 166.01, 138.69, 138.01, 134.99, 132.58, 129.08, 128.64, 127.82, 124.51, 123.98, 120.23, 21.39;

MS (EI) *m/z* = 211.10 (M⁺).



3-Methyl-*N*-phenylbenzamide (3ca)^[2]


According to the general procedure using (1H-pyrazol-1-yl)(*m*-tolyl)methanone (186 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ca** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (116 mg, 0.55 mmol, 55%).

m.p. 125-126 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.21 (s, 1H), 7.81 (d, *J* = 3.3 Hz, 1H), 7.80 – 7.78 (m, 2H), 7.76 (d, *J* = 6.3 Hz, 1H), 7.43 – 7.38 (m, 2H), 7.37 – 7.34 (m, 2H), 7.10 (tt, *J* = 7.4, 1.2 Hz, 1H), 2.40 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.67, 139.24, 137.67, 135.02, 132.09, 128.57, 128.26, 128.13, 124.81, 123.58, 120.33, 20.96;

MS (EI) *m/z* = 211.10 (M⁺).



4-Methyl-*N*-phenylbenzamide (**3da**)^[2]


According to the general procedure using (1H-pyrazol-1-yl)(*p*-tolyl)methanone (186 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3da** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (148 mg, 0.73 mmol, 73%).

m.p. 145-146 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.15 (s, 1H), 7.89 – 7.87 (m, 2H), 7.79 – 7.77 (m, 2H), 7.36 – 7.32 (m, 4H), 7.09 (tt, *J* = 7.4, 2.5 Hz, 1H), 2.39 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.33, 141.53, 139.24, 132.08, 128.88, 128.56, 127.68, 123.52, 120.34, 21.00;

MS (EI) *m/z* = 211.10 (M⁺).



4-(*tert*-Butyl)-*N*-phenylbenzamide (**3ea**)^[2]


According to the general procedure using (4-(*tert*-butyl)phenyl)(1H-pyrazol-1-yl)methanone (228 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ea** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (197 mg, 0.78 mmol, 78%).

m.p. 123-125 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.17 (s, 1H), 7.90 – 7.88 (m, 2H), 7.79 – 7.77 (m, 2H), 7.55 – 7.53 (m, 2H), 7.36 – 7.33 (m, 2H), 7.09 (tt, *J* = 7.4, 1.2 Hz, 1H), 1.32 (s, 9H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.49, 154.36, 139.27, 132.30, 128.56, 127.51, 125.12, 123.50, 120.25, 34.66, 30.93;

MS (EI) $m/z = 253.15$ (M^+).



4-Methoxy-*N*-phenylbenzamide (**3fa**)^[2]


According to the general procedure using (4-methoxyphenyl)(1H-pyrazol-1-yl)methanone (202 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3fa** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (3:1) and obtained as a white solid (173 mg, 0.76 mmol, 76%).

m.p. 160-161 °C;

^1H NMR (500 MHz, CDCl_3) δ 7.84 (m, 3H), 7.63 (d, $J = 8.0$ Hz, 2H), 7.35 (t, $J = 7.8$ Hz, 2H), 7.13 (t, $J = 7.4$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 2H), 3.86 (s, 3H);

^{13}C NMR (126 MHz, CDCl_3) δ 165.42, 162.60, 138.25, 129.19, 129.07, 127.27, 124.48, 120.34, 114.10, 55.62;

MS (EI) $m/z = 227.09$ (M^+).



3,4-Dimethoxy-*N*-phenylbenzamide (**3ga**)^[3]


According to the general procedure using (3,4-dimethoxyphenyl)(1H-pyrazol-1-yl)methanone (232 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ga** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (3:1) and obtained as a white solid (184 mg, 0.72 mmol, 72%).

m.p. 174-175 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.06 (s, 1H), 7.77 – 7.75 (m, 2H), 7.63 (dd, $J = 8.4, 2.1$ Hz, 1H), 7.54 (d, $J = 2.2$ Hz, 1H), 7.35 (t, $J = 7.9$ Hz, 2H), 7.10 – 7.07 (m, 2H), 3.85 (s, 3H), 3.84 (s, 3H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 164.88, 151.61, 148.29, 139.27, 128.53, 126.99, 123.46, 121.00, 120.46, 111.04, 110.88, 55.66, 55.62;

MS (EI) $m/z = 257.11$ (M^+).



4-(Dimethylamino)-*N*-phenylbenzamide (**3ha**)^[4]


According to the general procedure using (4-(dimethylamino)phenyl)(1H-pyrazol-1-yl)methanone (215 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ha** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (154 mg, 0.64 mmol, 64%).

m.p. 181-182 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 9.85 (s, 1H), 7.89 – 7.86 (m, 2H), 7.78 – 7.76 (m, 2H), 7.33 – 7.29 (m, 2H), 7.05 (tt, *J* = 7.4, 1.2 Hz, 1H), 6.77 – 6.74 (m, 2H), 3.00 (s, 6H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.19, 152.37, 139.71, 129.12, 128.45, 122.96, 121.08, 120.18, 110.75, 39.69;

MS (EI) *m/z* = 240.13 (M⁺).



N-Phenyl-(1,1'-biphenyl)-4-carboxamide (**3ia**)^[2]


According to the general procedure using [1,1'-biphenyl]-4-yl(1H-pyrazol-1-yl)methanone (248 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ia** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (207 mg, 0.76 mmol, 76%).

m.p. 222-223 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.30 (s, 1H), 8.09 – 8.06 (m, 2H), 7.85 – 7.81 (m, 4H), 7.77 – 7.75 (m, 2H), 7.53 – 7.49 (m, 2H), 7.44 – 7.41 (m, 1H), 7.38 – 7.35 (m, 2H), 7.11 (tt, *J* = 7.4, 2.5 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.18, 143.10, 139.21, 139.12, 133.73, 129.07, 128.62, 128.38, 128.15, 126.92, 126.59, 123.67, 120.39;

MS (EI) *m/z* = 273.12 (M⁺).



N-Phenyl-2-naphthamide (**3ja**)^[2]


According to the general procedure using naphthalen-2-yl(1H-pyrazol-1-yl)methanone (222 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ja** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (217 mg, 0.88 mmol, 88%).

m.p. 168-169 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.43 (s, 1H), 8.59 (s, 1H), 8.10 – 8.01 (m, 4H), 7.85 – 7.83 (m, 2H), 7.67 – 7.61 (m, 2H), 7.40 – 7.36 (m, 2H), 7.12 (tt, *J* = 7.4, 1.2 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.59, 139.24, 134.26, 132.29, 132.08, 128.94, 128.64, 128.00, 127.95, 127.80, 127.67, 126.84, 124.46, 123.68, 120.37;

MS (EI) *m/z* = 247.10 (M⁺).



4-Iodo-*N*-phenylbenzamide (**3ka**)^[4]


According to the general procedure using (4-iodophenyl)(1H-pyrazol-1-yl)methanone (298 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ka** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (239 mg, 0.74 mmol, 74%).

m.p. 205-207 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.28 (s, 1H), 7.93 – 7.91 (m, 2H), 7.77 – 7.74 (m, 4H), 7.37 – 7.33 (m, 2H), 7.11 (tt, *J* = 7.4, 2.5 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.79, 138.96, 137.24, 134.31, 129.61, 128.61, 123.79, 120.40, 99.24;

MS (EI) *m/z* = 322.98 (M⁺).




4-Bromo-*N*-phenylbenzamide (**3la**)^[4]

According to the general procedure using (4-bromophenyl)(1H-pyrazol-1-yl)methanone (251 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3la** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (183 mg, 0.78 mmol, 78%). m.p. 202-203 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.31 (s, 1H), 7.92 – 7.91 (m, 2H), 7.77 – 7.74 (m, 4H), 7.36 (t, *J* = 7.5 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.53, 138.95, 134.01, 131.38, 129.79, 128.62, 125.30, 123.82, 120.41;

MS (EI) $m/z = 274.99$ (M^+).



4-Chloro-*N*-phenylbenzamide (**3ma**)^[4]


According to the general procedure using (4-chlorophenyl)(1H-pyrazol-1-yl)methanone (207 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ma** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (208 mg, 0.90 mmol, 90%).

m.p. 199-201 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.30 (s, 1H), 8.00 – 7.97 (m, 2H), 7.77 – 7.75 (m, 2H), 7.62 – 7.59 (m, 2H), 7.38 – 7.34 (m, 2H), 7.13 – 7.09 (m, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.42, 138.96, 136.37, 133.65, 129.62, 128.62, 128.45, 123.82, 120.41;

MS (EI) $m/z = 231.05$ (M^+).



4-Fluoro-*N*-phenylbenzamide (**3na**)^[2]


According to the general procedure using (4-fluorophenyl)(1H-pyrazol-1-yl)methanone (190 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3na** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (183 mg, 0.85 mmol, 85%).

m.p. 183-185 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.26 (s, 1H), 8.06 – 8.02 (m, 2H), 7.78 – 7.75 (m, 2H), 7.39 – 7.33 (m, 4H), 7.10 (tt, $J = 7.4, 1.2$ Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.43, 164.06(d, $J = 249.5$ Hz), 139.07, 131.40 (d, $J = 3.8$ Hz), 130.39 (d, $J = 8.8$ Hz), 128.60, 123.72, 120.41, 115.31 (d, $J = 21.4$ Hz);

MS (EI) $m/z = 215.07$ (M^+).m



N-Phenyl-4-(trifluoromethyl)benzamide (**3oa**)^[2]


According to the general procedure using (1H-pyrazol-1-yl)(4-(trifluoromethyl)phenyl)methanone (240 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **30a** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (215 mg, 0.81 mmol, 81%).

m.p. 197-199 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.46 (s, 1H), 8.16 – 8.14 (m, 2H), 7.92 – 7.90 (m, 2H), 7.80 – 7.77 (m, 2H), 7.39 – 7.33 (m, 2H), 7.15 – 7.11 (m, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.39, 138.83, 138.80, 131.36 (q, *J* = 31.5 Hz), 128.68, 128.59, 125.38 (q, *J* = 3.8 Hz), 124.02, 123.94 (q, *J* = 273.4 Hz), 120.46;

MS (EI) *m/z* = 265.07 (M⁺).



4-Cyano-*N*-phenylbenzamide (**3pa**)^[2]


According to the general procedure using 4-(1H-pyrazole-1-carbonyl)benzonitrile (197 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3pa** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (195 mg, 0.88 mmol, 88%).

m.p. 175-177 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.47 (s, 1H), 8.11 (d, *J* = 8.5 Hz, 2H), 8.02 (d, *J* = 8.3 Hz, 2H), 7.78 (d, *J* = 7.6 Hz, 2H), 7.39 – 7.35 (t, *J* = 7.4 Hz, 2H), 7.13 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 164.13, 138.98, 138.75, 132.44, 128.68, 128.53, 124.09, 120.46, 118.32, 113.84;

MS (EI) *m/z* = 222.08 (M⁺).



Methyl-4-(phenylcarbamoyl)benzoate (**3qa**)^[5]


According to the general procedure using methyl 4-(1H-pyrazole-1-carbonyl)benzoate (230 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3qa** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (196 mg, 0.77 mmol, 77%).

m.p. 185-187 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.43 (s, 1H), 8.11 – 8.06 (m, 4H), 7.79 – 7.78 (m, 2H), 7.39 – 7.35 (m, 2H), 7.12 (tt, *J* = 7.3, 1.2 Hz, 1H), 3.90 (s, 3H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.69, 164.69, 139.07, 138.89, 132.01, 129.17, 128.65, 128.07, 123.95, 120.44, 52.42;

MS (EI) $m/z = 255.09$ (M^+).



4-Acetyl-N-phenylbenzamide (**3ra**)^[4]


According to the general procedure using 4-(1H-pyrazole-1-carbonyl)benzotrile (214 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ra** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (177 mg, 0.74 mmol, 74%).

m.p. 125-127 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.41 (s, 1H), 8.10 – 8.06 (m, 4H), 7.80 – 7.78 (m, 2H), 7.39 – 7.35 (m, 2H), 7.14 – 7.11 (m, 1H), 2.64 (s, 3H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 197.70, 164.75, 138.92, 138.83, 138.76, 128.65, 128.17, 128.01, 123.93, 120.45, 26.99;

MS (EI) $m/z = 239.09$ (M^+).



N,2-Diphenylacetamide (**3sa**)^[3]


According to the general procedure using 2-phenyl-1-(1H-pyrazol-1-yl)ethan-1-one (186 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3sa** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (156 mg, 0.74 mmol, 74%).

m.p. 118-119 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.17 (s, 1H), 7.63 (dd, $J = 8.7, 1.2$ Hz, 2H), 7.37 – 7.27 (m, 6H), 7.25 – 7.22 (m, 1H), 7.05 – 7.01 (m, 1H), 3.66 (s, 2H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 169.10, 139.25, 136.03, 129.10, 128.70, 128.29, 126.51, 123.20, 119.13, 43.37;

MS (EI) $m/z = 211.10$ (M^+).



***N*-Phenylpentanamide (3ta)^[6]**


According to the general procedure using 1-(1H-pyrazol-1-yl)pentan-1-one (152 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ta** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (110 mg, 0.62 mmol, 62%).

m.p. 94-96 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 9.84 (s, 1H), 7.61 – 7.59 (m, 2H), 7.29 – 7.25 (m, 2H), 7.01 (tt, *J* = 7.4, 1.2 Hz, 1H), 2.30 (t, *J* = 7.4 Hz, 2H), 1.61 – 1.55 (m, 2H), 1.36 – 1.29 (m, 2H), 0.89 (t, *J* = 7.3 Hz, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 171.23, 139.38, 128.58, 122.85, 119.01, 36.14, 27.27, 21.84, 13.72;

MS (EI) *m/z* = 177.12 (M⁺).



***N*-Phenylisobutyramide (3ua)^[4]**


According to the general procedure using 2-methyl-1-(1H-pyrazol-1-yl)propan-1-one (138 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3ua** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (112 mg, 0.69 mmol, 69%).

m.p. 112-114 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 9.80 (s, 1H), 7.63 – 7.61 (m, 2H), 7.30 – 7.26 (m, 2H), 7.01 (tt, *J* = 7.5, 1.2 Hz, 1H), 2.59 (hept, *J* = 6.8 Hz, 1H), 1.10 (d, *J* = 6.7 Hz, 6H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 175.17, 139.46, 128.58, 122.87, 119.11, 34.91, 19.49;

MS (EI) *m/z* = 163.10 (M⁺).



***N*-Phenylpivalamide (3va)^[4]**


According to the general procedure using 2,2-dimethyl-1-(1H-pyrazol-1-yl)propan-1-one (152 mg, 1.0 mmol) and nitrobenzene (123 mg, 1.0 mmol), the product **3va** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (101 mg, 0.57 mmol, 57%).

m.p. 132-134 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 9.17 (s, 1H), 7.65 – 7.62 (m, 2H), 7.30 – 7.26 (m, 2H), 7.03 (tt, *J* = 7.3, 1.3Hz, 1H), 1.23 (s, 9H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 176.38, 139.36, 128.35, 123.10, 120.23, 39.11, 27.20;

MS (EI) $m/z = 177.12$ (M^+).



***N*-(*p*-Tolyl)benzamide (3ab)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-methyl-4-nitrobenzene (137 mg, 1.0 mmol), the product **3ab** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (146 mg, 0.69 mmol, 69%).

m.p. 154-156 °C;

¹H NMR (500 MHz, CDCl₃) δ 7.93 (s, 1H), 7.85 (dd, *J* = 8.3, 1.4 Hz, 2H), 7.54 – 7.51 (m, 3H), 7.46 – 7.43 (m, 2H), 7.15 (d, *J* = 8.3 Hz, 2H), 2.34 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 165.84, 135.50, 135.20, 134.34, 131.83, 129.68, 128.84, 127.14, 120.47, 21.03;

MS (EI) $m/z = 211.10$ (M^+).



***N*-(4-Methoxyphenyl)benzamide (3ac)^[2]**


According to the general procedure, using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol), and 1-methoxy-4-nitrobenzene (153 mg, 1.0 mmol), the product **3ac** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (3:1) and obtained as a white solid (143 mg, 0.63 mmol, 63%).

m.p. 163-164 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.13 (s, 1H), 7.96 – 7.94 (m, 2H), 7.70 – 7.67 (m, 2H), 7.57 (m, 1H), 7.52 (m, 2H), 6.95 – 6.91 (m, 2H), 3.75 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.09, 155.54, 135.05, 132.23, 131.36, 128.33, 127.54, 121.97, 113.72, 55.17;

MS (EI) $m/z = 227.09$ (M^+).



***N*-(Naphthalen-2-yl)benzamide (3ad)^[7]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 2-nitronaphthalene (173 mg, 1.0 mmol), the product **3ad** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (146 mg, 0.59 mmol, 59%).

m.p. 158-159 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.44 (s, 1H), 8.11 – 8.09 (m, 2H), 8.01 – 7.97 (m, 2H), 7.87 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.65 – 7.61 (m, 2H), 7.59 – 7.53 (m, 5H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 166.16, 134.45, 133.85, 133.76, 131.66, 129.23, 128.45, 128.07, 127.79, 126.28, 126.06, 125.97, 125.54, 123.92, 123.33;

MS (EI) *m/z* = 247.10 (M⁺).



***N*-(3-Bromo-4-methylphenyl)benzamide (3ae)**^[8]


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 2-bromo-1-methyl-4-nitrobenzene (216 mg, 1.0 mmol), the product **3ae** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (237 mg, 0.82 mmol, 82%).

m.p. 135-137 °C;

¹H NMR (500 MHz, CDCl₃) δ 7.93 (s, 1H), 7.88 (d, *J* = 2.2 Hz, 1H), 7.84 (dd, *J* = 8.4, 1.3 Hz, 2H), 7.55 – 7.52 (m, 1H), 7.48 – 7.44 (m, 3H), 7.18 (dd, *J* = 8.2, 0.9 Hz, 1H), 2.37 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 165.85, 136.83, 134.73, 134.13, 132.10, 130.95, 128.93, 127.16, 124.93, 124.13, 119.39, 22.43;

MS (EI) *m/z* = 289.01 (M⁺).



***N*-(3-Chloro-4-methylphenyl)benzamide (3af)**^[9]


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 2-chloro-1-methyl-4-nitrobenzene (172 mg, 1.0 mmol), the product **3af** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (194 mg, 0.79 mmol, 79%).

m.p. 120-121 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.32 (s, 1H), 7.97 – 7.94 (m, 3H), 7.64 – 7.58 (m, 2H), 7.55 – 7.51 (m, 2H), 7.31 (dd, *J* = 8.3, 0.8 Hz, 1H), 2.90 (s, 3H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.57, 138.33, 134.63, 132.87, 131.70, 131.04, 130.24, 128.41, 127.64, 120.19, 118.86, 18.96;

MS (EI) $m/z = 245.06$ (M^+).



***N*-(4-Fluorophenyl)benzamide (3ag)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-fluoro-4-nitrobenzene (141 mg, 1.0 mmol), the product **3ag** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (148 mg, 0.69 mmol, 69%).

m.p. 177-178 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.30 (s, 1H), 7.97 – 7.94 (m, 2H), 7.82 – 7.78 (m, 2H), 7.61 – 7.57 (m, 1H), 7.55 – 7.51 (m, 2H), 7.22 – 7.17 (m, 2H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.47, 158.29 (d, $J = 240.7$ Hz), 135.53 (d, $J = 7.7$ Hz), 134.81, 131.58, 128.39, 127.62, 122.17 (d, $J = 10.1$ Hz), 115.17 (d, $J = 21.4$ Hz);

MS (EI) $m/z = 215.07$ (M^+).



***N*-(4-Chlorophenyl)benzamide (3ah)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-chloro-4-nitrobenzene (158 mg, 1.0 mmol), the product **3ah** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (136 mg, 0.59 mmol, 59%).

m.p. 191-192 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.37 (s, 1H), 7.97 – 7.94 (m, 2H), 7.85 – 7.82 (m, 2H), 7.61 – 7.58 (m, 1H), 7.55 – 7.51 (m, 2H), 7.42 – 7.39 (m, 2H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.66, 138.16, 134.72, 131.69, 128.51, 128.41, 127.68, 127.26, 121.84;

MS (EI) $m/z = 231.05$ (M^+).



***N*-(3-Bromophenyl)benzamide (3ai)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-bromo-3-nitrobenzene (202 mg, 1.0 mmol), the product **3ai** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (170 mg, 0.62 mmol, 62%).

m.p. 132-133 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.40 (s, 1H), 8.14 (t, *J* = 1.9 Hz, 1H), 7.97 – 7.96 (m, 2H), 7.79 – 7.77 (m, 1H), 7.62 – 7.58 (m, 1H), 7.56 – 7.52 (m, 2H), 7.32 (t, *J* = 7.9 Hz, 1H), 7.30 – 7.28 (m, 1H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.78, 140.82, 134.56, 131.78, 130.58, 128.42, 127.71, 126.20, 122.56, 121.42, 118.99;

MS (EI) *m/z* = 274.99 (M⁺).



***N*-(4-Bromophenyl)benzamide (3aj)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-bromo-4-nitrobenzene (202 mg, 1.0 mmol), the product **3aj** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (181 mg, 0.66 mmol, 66%).

m.p. 201-203 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.37 (s, 1H), 7.96 – 7.94 (m, 2H), 7.79 – 7.76 (m, 2H), 7.62 – 7.58 (m, 1H), 7.55 – 7.52 (m, 4H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.65, 138.58, 134.70, 131.70, 131.42, 128.40, 127.67, 122.20, 115.31;

MS (EI) *m/z* = 274.99 (M⁺).



***N*-(4-Iodophenyl)benzamide (3ak)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-iodo-4-nitrobenzene (249 mg, 1.0 mmol), the product **3ak** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (210 mg, 0.65 mmol, 65%).

m.p. 218-220 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.34 (s, 1H), 7.95 (d, *J* = 7.0 Hz, 2H), 7.69 (d, *J* = 8.9 Hz, 2H), 7.64 (d, *J* = 8.9 Hz, 2H), 7.60 (t, *J* = 7.3 Hz, 1H), 7.54 – 7.52 (m, 2H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 165.64, 139.05, 137.26, 134.72, 131.69, 128.40, 127.67, 122.45, 87.30;

MS (EI) *m/z* = 322.98 (M⁺).



***N*-(4-Acetylphenyl)benzamide (3al)**^[5]


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-(4-nitrophenyl)ethan-1-one (165 mg, 1.0 mmol), the product **3al** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (125 mg, 0.52 mmol, 52%).

m.p. 197-198 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.56 (s, 1H), 7.99 – 7.94 (m, 6H), 7.63 – 7.60 (m, 1H), 7.57 – 7.53 (m, 2H), 2.55 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 196.58, 165.99, 143.62, 134.58, 132.01, 131.88, 129.29, 128.44, 127.81, 119.43, 26.46;

MS (EI) *m/z* = 239.09 (M⁺).



***N*-(4-Cyanophenyl)benzamide (3am)**^[2]


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 4-nitrobenzonitrile (148 mg, 1.0 mmol), the product **3am** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (162 mg, 0.73 mmol, 73%).

m.p. 168-170 °C;

¹H NMR (500 MHz, (CD₃)₂SO) δ 10.64 (s, 1H), 8.01 – 7.99 (m, 2H), 7.97 – 7.95 (m, 2H), 7.83 – 7.81 (m, 2H), 7.64 – 7.61 (m, 1H), 7.57 – 7.54 (m, 2H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 166.19, 143.51, 134.39, 133.12, 132.04, 128.49, 127.84, 120.17, 119.08, 105.34;

MS (EI) $m/z = 222.08$ (M^+).



***N*-(4-Vinylphenyl)benzamide (3an)^[5]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-nitro-4-vinylbenzene (149 mg, 1.0 mmol), the product **3an** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (87 mg, 0.39 mmol, 39%).

m.p. 149-151 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 10.29 (s, 1H), 7.94 – 7.96 (m, 2H), 7.78 (d, $J = 8.7$ Hz, 2H), 7.59 (t, $J = 7.3$ Hz, 1H), 7.52 – 7.55 (m, 2H), 7.46 (d, $J = 8.8$ Hz, 2H), 6.70 (dd, $J = 17.7$, 11.0 Hz, 1H), 5.77 (dd, $J = 17.7$, 2.2 Hz, 1H), 5.20 (dd, $J = 11.0$, 1.0 Hz, 1H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.50, 138.92, 136.19, 134.90, 132.53, 131.57, 128.38, 127.64, 126.44, 120.23, 112.94;

MS (EI) $m/z = 223.10$ (M^+).



***N*-Cyclohexylbenzamide (3ao)^[2]**


According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and nitrocyclohexane (129 mg, 1.0 mmol), the product **3ao** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a white solid (120 mg, 0.59 mmol, 59%).

m.p. 148-149 °C;

^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$) δ 8.17 (d, $J = 8.0$ Hz, 1H), 7.84 – 7.82 (m, 2H), 7.50 (t, $J = 7.3$ Hz, 1H), 7.45 - 7.42 (m, 2H), 3.79 – 3.72 (m, 1H), 1.83 – 1.80 (m, 2H), 1.74 – 1.72 (m, 2H), 1.60 (d, $J = 12.3$ Hz, 1H), 1.35 – 1.23 (m, 4H), 1.16 – 1.11 (m, 1H);

^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.31, 134.90, 130.87, 128.09, 127.24, 48.30, 32.41, 25.26, 24.95;

MS (EI) $m/z = 203.13$ (M^+).




N-Hexylbenzamide (3ap)^[2]

According to the general procedure using phenyl(1H-pyrazol-1-yl)methanone (172 mg, 1.0 mmol) and 1-nitrohexane (131 mg, 1.0 mmol), the product **3ap** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (9:1) and obtained as a yellow oil (141 mg, 0.69 mmol, 69%).

¹H NMR (500 MHz, (CD₃)₂SO) δ 8.43 (t, *J* = 5.7 Hz, 1H), 7.88 – 7.82 (m, 2H), 7.49 (t, *J* = 7.3 Hz, 1H), 7.44 (t, 7.3 Hz, 2H), 3.29 – 3.22 (m, 2H), 1.51 (quin, *J* = 7.7 Hz, 2H), 1.34 – 1.23 (m, 6H), 0.89 – 0.82 (m, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 166.04, 134.75, 130.88, 128.14, 127.10, 39.20, 31.04, 29.11, 26.19, 22.07, 13.87;

MS (EI) *m/z* = 205.15(M⁺).




N-(4-methoxyphenyl)acetamide (3xt)^[10]

According to the general procedure using 1-(1H-pyrazol-1-yl)ethan-1-one (110 mg, 1.0 mmol) and 1-methoxy-4-nitrobenzene (153 mg, 1.0 mmol), the product **3xt** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (3:1) and obtained as a brown solid (135 mg, 0.82 mmol, 82%).

¹H NMR (500 MHz, (CD₃)₂SO) δ 9.76 (s, 1H), 7.49 – 7.46 (m, 2H), 6.87 – 6.84 (m, 2H), 3.70 (s, 3H), 2.00 (s, 3H);

¹³C NMR (126 MHz, (CD₃)₂SO) δ 167.72, 155.01, 132.54, 120.53, 113.77, 55.11, 23.79;

MS (EI) *m/z* = 165.08(M⁺).




N-(4-hydroxyphenyl)acetamide (3xu)^[10]

4-Nitrophenol (139 mg, 1.0 mmol) and $B_2(OH)_4$ (269 mg, 3.0 mmol, 3.0 equiv) were dissolved in DMF (5 mL, 0.2M) and stirred at 100 °C for 6 h. 1-(1H-pyrazol-1-yl)ethan-1-one (110 mg, 1.0 mmol) was added to the reaction mixture and stirred at 70 °C for 18 h. The product **3xu** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (1:1) and obtained as a brown solid (109 mg, 0.72 mmol, 72%).

1H NMR (500 MHz, $(CD_3)_2SO$) δ 9.63 (s, 1H), 9.12 (s, 1H), 7.35 – 7.32 (m, 2H), 6.69 – 6.65 (m, 2H), 1.97 (s, 3H);

^{13}C NMR (126 MHz, $(CD_3)_2SO$) δ 167.50, 153.11, 131.04, 120.81, 114.99, 23.74;

MS (EI) m/z = 151.06(M^+).



4-chloro-*N*-(2-hydroxyethyl)cyclohexa-2,4-diene-1-carboxamide (**3mv**)^[11]

2-Nitroethan-1-ol (91 mg, 1.0 mmol) and $B_2(OH)_4$ (269 mg, 3.0 mmol, 3.0 equiv) were dissolved in DMF (5 mL, 0.2M) and stirred at 100 °C for 6 h. (4-chlorophenyl)(1H-pyrazol-1-yl)methanone (207 mg, 1.0 mmol) was added to the reaction mixture and stirred at 70 °C for 18 h. The product **3mv** was purified by chromatography on silica gel eluting with *n*-hexane/EtOAc (1:4) and obtained as a white solid (124 mg, 0.62 mmol, 62%).

1H NMR (500 MHz, $(CD_3)_2SO$) δ 8.55 (t, J = 5.8 Hz, 1H), 7.93 – 7.90 (m, 2H), 7.58 – 7.55 (m, 2H), 4.77 (t, 5.6 Hz, 1H), 3.56 (q, J = 6.0 Hz, 2H), 3.37 (q, J = 6.0 Hz, 2H);

^{13}C NMR (126 MHz, $(CD_3)_2SO$) δ 165.28, 135.90, 133.31, 129.15, 128.30, 59.69, 42.26;



MS (EI) m/z = 201.06 (M^+).

5. References

1. H. Chen, D-H. Chen and P-Q. Huang, *Sci. China Chem.* 2020, **63**, 370-376.
2. D. Joseph, M. S. Park and S. Lee, *Org. Biomol. Chem.* 2021, **19**, 6227-6232.
3. Z. Yang, H. Zhou, L. Wang, J. Zhang, H. Xie, Y. Liu, J. Zeng and P. Cheng, *RSC Adv.* 2022, **12**, 17190-17193.
4. H. Yu, X. Zhang, L. Li, H. Luo and G. Che, *Org. Chem. Front.* 2023, **10**, 686-698.
5. J. – J. Tang, X. Yu, Y. Yamamoto and M. Bao, *ACS Catal.* 2021, **11**, 13955–13961.
6. V. Heranadez-Olmos, J. Heering, V. Planz, T. Liu, A. Kaps, R. Rajkumar, M. Gramzow, A. Kaiser, M. Schubert-Zsilavecs, M. J. Parnham, M. Windbergs, D. Steinhilber and E. Proschak, *J. Med. Chem.* 2020, **63**, 11548–11572.
7. S. A. Rzhavskiy, A. A. Ageshina, G. A. Chesnokov, P. S. Griбанov, M. A. Topchiy, M. S. Nechaev and A. F. Asachenko, *RSC Adv.* 2019, **9**, 1536-1540.
8. C. W. Cheung, M. L. Ploeger and X. Hu, *ACS Catal.* 2017, **7**, 7092–7096.
9. W. C. Fu and T. F. Jamison, *Org. Lett.* 2019, **21**, 6112–6116.
10. J. Xu, Y. Gao, Z. Li, J. Liu, T. Guo, L. Zhang, H. Wang, Z. Zhang and K. Guo, *Eur. J. Org. Chem.* 2020, 311–315.
11. V. R. Chintareddy, H. - A. Ho, A. D. Sadow and J. G. Verkade, *Tetrahedron Lett.* 2011, **52**, 6523-6529.


6. ¹H and ¹³C NMR spectra of products

N-Phenylbenzamide (3a)




2-Methyl-N-phenylbenzamide (3ba)

□□ □□□




¹³C NMR




3-Methyl-N-phenylbenzamide (3ca)



□□ □□□




¹³C NMR




4-Methyl-N-phenylbenzamide (3da)



4-(Tert-butyl)-*N*-phenylbenzamide (3ea)






$^{13}\text{C NMR}$




4-Methoxy-*N*-phenylbenzamide (3fa)


$^1\text{H NMR}$











¹³C NMR












¹³C NMR









¹³C NMR



4-Chloro-*N*-phenylbenzamide (3ma)





¹³C NMR




4-Fluoro-*N*-phenylbenzamide


□ □ □ □





N-Phenyl-4-(trifluoromethyl)benzamide (30a)





¹³C NMR





4-Cyano-N-phenylbenzamide (3pa)





Methyl-4-(phenylcarbamoyl)benzoate (3qa)




4-Acetyl-N-phenylbenzamide (3ra)






N-Phenylpentanamide (3ta)




¹³C NMR






N-Phenylisobutyramide (3ua)



□ □ □ □




¹³C NMR










¹³C NMR




N-(Naphthalen-2-yl)benzamide (3ad)



N-(3-Bromo-4-methylphenyl)benzamide (3ae)





¹³C NMR




N-(3-Chloro-4-methylphenyl)benzamide (3af)


¹³C NMR






¹³C NMR








¹³C NMR





¹³C NMR





N-(3-Bromophenyl)benzamide (3ai)




N-(4-Bromophenyl)benzamide (3aj)




N-(4-Iodophenyl)benzamide (3ak)




N-(4-Acetylphenyl)benzamide (3al)






¹³C NMR










Cyanophenyl)benzamide (3am)














methoxyphenyl)acetamide (3xt)



N-(4-hydroxyphenyl)acetamide (3xu)



4-chloro-N-(2-hydroxyethyl)cyclohexa-2,4-diene-1-carboxamide (3mv)

